Characteristics of a Chronic Cough Population Participating in Two Large Phase III Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist | Zendy

AI Assistant Blog Pricing

Open Access

Characteristics of a Chronic Cough Population Participating in Two Large Phase III Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist

Author(s) -

Peter V. Dicpinigaitis,

Lorcan McGarvey,

Alyn H. Morice,

John A. Smith,

SS Birring,

Ian Pavord,

Beata Iskold,

Anjela Tzontcheva,

Q. Li,

Carmen La Rosa,

David Muccino

Publication year - 2021

Language(s) - English

Resource type - Conference proceedings

DOI - 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2360

Subject(s) - antagonist , chronic cough , medicine , clinical trial , receptor , asthma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.